Who are phenytoin and probenecid's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/phenytoin-and-probenecid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

phenytoin and probenecid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

phenytoin and probenecid (phenytoin and probenecid) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant and uricosuric agent combination. Area: Neurology and Rheumatology.

marketed Anticonvulsant and uricosuric agent combination Voltage-gated sodium channels (phenytoin); organic acid transporter (probenecid) Neurology and Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

phenytoin and probenecid (phenytoin and probenecid) — Jim McAuley. Phenytoin is an anticonvulsant that stabilizes neuronal membranes and reduces seizure activity, while probenecid is a uricosuric agent that increases uric acid excretion and can inhibit renal tubular secretion of certain drugs.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
phenytoin and probenecid TARGET	phenytoin and probenecid	Jim McAuley	marketed	Anticonvulsant and uricosuric agent combination	Voltage-gated sodium channels (phenytoin); organic acid transporter (probenecid)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant and uricosuric agent combination class)

Jim McAuley · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). phenytoin and probenecid — Competitive Intelligence Brief. https://druglandscape.com/ci/phenytoin-and-probenecid. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab